FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096514095> ?p ?o ?g. }

• W2096514095 endingPage "5483" @default.
• W2096514095 startingPage "5474" @default.
• W2096514095 abstract "Purpose We studied the safety, clinical activity, and pharmacokinetics (PK) of AG-013736, an oral receptor tyrosine kinase inhibitor of vascular endothelial cell growth factor, platelet-derived growth factor, and c-Kit, in patients with advanced cancer. Patients and Methods Patients received fixed doses of AG-013736 orally in 28-day cycles. In the first cohort, patients initially received two single test doses of AG-013736 (10 and 30 mg); subsequent dosing was determined by individual PK parameters. Doses in subsequent cohorts were assigned by using a traditional dose-escalation/de-escalation rule based on observed toxicities in the current and previous cohorts. PK analysis included evaluation of the effect of food and antacid. Results Thirty-six patients received AG-013736 at doses ranging from 5 to 30 mg by mouth twice daily. The dose-limiting toxicities observed included hypertension, hemoptysis, and stomatitis and were seen primarily at the higher dose levels. The observed hypertension was manageable with medication. Stomatitis was generally tolerable and managed by dose reduction or drug holidays. AG-013736 was absorbed rapidly, with peak plasma concentrations observed within 2 to 6 hours after dosing. The maximum-tolerated dose and recommended phase II dose of AG-013736 is 5 mg, twice daily, administered in the fasted state. No significant drug interaction with antacid was seen. There were three confirmed partial responses and other evidence of clinical activity. Conclusion In this study, we have demonstrated clinical activity and safety of AG-013736 in patients with advanced solid tumors and identified the dose for phase II testing. The unique phase I study design allowed early identification of important absorption and metabolic issues critical to phase II testing of this agent." @default.
• W2096514095 created "2016-06-24" @default.
• W2096514095 creator A5008593691 @default.
• W2096514095 creator A5009862118 @default.
• W2096514095 creator A5017187936 @default.
• W2096514095 creator A5030084075 @default.
• W2096514095 creator A5042584872 @default.
• W2096514095 creator A5061697254 @default.
• W2096514095 creator A5063334369 @default.
• W2096514095 creator A5078449638 @default.
• W2096514095 creator A5085872163 @default.
• W2096514095 creator A5090188675 @default.
• W2096514095 date "2005-08-20" @default.
• W2096514095 modified "2023-10-14" @default.
• W2096514095 title "Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results" @default.
• W2096514095 cites W1837651204 @default.
• W2096514095 cites W1964005024 @default.
• W2096514095 cites W1966290213 @default.
• W2096514095 cites W1977887541 @default.
• W2096514095 cites W1985528986 @default.
• W2096514095 cites W1985804036 @default.
• W2096514095 cites W1986315644 @default.
• W2096514095 cites W2000307014 @default.
• W2096514095 cites W2012390831 @default.
• W2096514095 cites W2015809080 @default.
• W2096514095 cites W2047140207 @default.
• W2096514095 cites W2047679549 @default.
• W2096514095 cites W2064360454 @default.
• W2096514095 cites W2068435205 @default.
• W2096514095 cites W2068835361 @default.
• W2096514095 cites W2070230256 @default.
• W2096514095 cites W2072179690 @default.
• W2096514095 cites W2073212944 @default.
• W2096514095 cites W2077129920 @default.
• W2096514095 cites W2088929622 @default.
• W2096514095 cites W2096704713 @default.
• W2096514095 cites W2109134893 @default.
• W2096514095 cites W2133602604 @default.
• W2096514095 cites W2139248078 @default.
• W2096514095 cites W2139716410 @default.
• W2096514095 cites W2145854263 @default.
• W2096514095 cites W2155591820 @default.
• W2096514095 cites W2157769714 @default.
• W2096514095 cites W2159789252 @default.
• W2096514095 cites W2168438265 @default.
• W2096514095 cites W2332652021 @default.
• W2096514095 cites W4250428608 @default.
• W2096514095 cites W4253705647 @default.
• W2096514095 cites W2246879735 @default.
• W2096514095 doi "https://doi.org/10.1200/jco.2005.04.192" @default.
• W2096514095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16027439" @default.
• W2096514095 hasPublicationYear "2005" @default.
• W2096514095 type Work @default.
• W2096514095 sameAs 2096514095 @default.
• W2096514095 citedByCount "455" @default.
• W2096514095 countsByYear W20965140952012 @default.
• W2096514095 countsByYear W20965140952013 @default.
• W2096514095 countsByYear W20965140952014 @default.
• W2096514095 countsByYear W20965140952015 @default.
• W2096514095 countsByYear W20965140952016 @default.
• W2096514095 countsByYear W20965140952017 @default.
• W2096514095 countsByYear W20965140952018 @default.
• W2096514095 countsByYear W20965140952019 @default.
• W2096514095 countsByYear W20965140952020 @default.
• W2096514095 countsByYear W20965140952021 @default.
• W2096514095 countsByYear W20965140952022 @default.
• W2096514095 countsByYear W20965140952023 @default.
• W2096514095 crossrefType "journal-article" @default.
• W2096514095 hasAuthorship W2096514095A5008593691 @default.
• W2096514095 hasAuthorship W2096514095A5009862118 @default.
• W2096514095 hasAuthorship W2096514095A5017187936 @default.
• W2096514095 hasAuthorship W2096514095A5030084075 @default.
• W2096514095 hasAuthorship W2096514095A5042584872 @default.
• W2096514095 hasAuthorship W2096514095A5061697254 @default.
• W2096514095 hasAuthorship W2096514095A5063334369 @default.
• W2096514095 hasAuthorship W2096514095A5078449638 @default.
• W2096514095 hasAuthorship W2096514095A5085872163 @default.
• W2096514095 hasAuthorship W2096514095A5090188675 @default.
• W2096514095 hasBestOaLocation W20965140951 @default.
• W2096514095 hasConcept C112705442 @default.
• W2096514095 hasConcept C121608353 @default.
• W2096514095 hasConcept C126322002 @default.
• W2096514095 hasConcept C2777288759 @default.
• W2096514095 hasConcept C2779051857 @default.
• W2096514095 hasConcept C2780035454 @default.
• W2096514095 hasConcept C2780590083 @default.
• W2096514095 hasConcept C535046627 @default.
• W2096514095 hasConcept C71924100 @default.
• W2096514095 hasConcept C90924648 @default.
• W2096514095 hasConcept C98274493 @default.
• W2096514095 hasConceptScore W2096514095C112705442 @default.
• W2096514095 hasConceptScore W2096514095C121608353 @default.
• W2096514095 hasConceptScore W2096514095C126322002 @default.
• W2096514095 hasConceptScore W2096514095C2777288759 @default.
• W2096514095 hasConceptScore W2096514095C2779051857 @default.
• W2096514095 hasConceptScore W2096514095C2780035454 @default.
• W2096514095 hasConceptScore W2096514095C2780590083 @default.
• W2096514095 hasConceptScore W2096514095C535046627 @default.

• next